HCM - Hutchison China MediTech Limited

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.99
+1.04 (+4.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close21.95
Open22.30
Bid22.09 x 800
Ask23.75 x 1100
Day's Range22.07 - 23.16
52 Week Range14.74 - 30.30
Volume524,527
Avg. Volume273,964
Market Cap3.246B
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-0.80
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.52
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review

    Based on the preset criteria, the IDMC recommended that the trial continue. FRUTIGA is a Phase III trial in China of fruquintinib in combination with paclitaxel (Taxol®) in the treatment of patients with advanced gastric adenocarcinoma or gastroesophageal junction (“GEJ”) adenocarcinoma who have progressed after first-line standard chemotherapy.

  • GlobeNewswire

    Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

    LONDON, June 01, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the.

  • GlobeNewswire

    Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20

    ― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease.

  • GlobeNewswire

    Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

    — First NDA filing of savolitinib globally — —  Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor — LONDON, May 29, 2020 --.

  • Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment
    SmarterAnalyst

    Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment

    Hutchison China MediTech (HCM) and BeiGene (BGNE) have now entered into a clinical collaboration agreement for the treatment of various solid tumor cancers.The collaboration will evaluate the safety, tolerability and efficacy of two of Chi-Med’s drug candidates, surufatinib and fruquintinib, combined with BeiGene’s anti-PD-1 antibody tislelizumab for cancer treatment in the US, Europe, China and Australia.Chi-Med and BeiGene each plan to explore development of the combination of these drug candidates in different indications and regions. The companies have agreed to provide mutual drug supply and other support.“We hope to understand and develop innovative combination therapies that may bring meaningful treatments to cancer patients around the world. Through this collaboration we plan to further evaluate tislelizumab in combination with oral VEGFR inhibitors to target a variety of solid tumor cancers,” said Lai Wang of BeiGene.Each of these three compounds are currently in late-stage global clinical development across many countries outside of China. Tislelizumab and fruquintinib have both been approved by the China National Medical Products Administration which is also currently reviewing the New Drug Application for surufatinib that was submitted late last year.Both companies currently score a bullish Strong Buy Street consensus. For instance, in the last three months, six analysts have published buy ratings on BeiGene vs 1 hold rating. With shares down 4% year-to-date, the average analyst price target indicates upside potential of 19%. (See BeiGene stock analysis on TipRanks).Maxim Group’s Jason McCarthy has a buy rating on BGNE with a $190 price target. He notes that Tislelizumab is currently being evaluated in 15 registration-enabling clinical trials in China and globally (11 P3 and 4 pivotal P2 trials).Related News: Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results In July Regeneron and Sanofi’s Dupixent Shows ‘Positive’ Trial Data, Meets Co-Primary Endpoints Regeneron To Repurchase $5 Billion Stake From Sanofi   More recent articles from Smarter Analyst: * Lear Corporation Set to Reopen Plant After Coronavirus Outbreak Kills 20 * Allogene Seeks To Raise $550 Million From Share Sale Priced At $47 * Zillow to Resume "iBuyer" Program in 4 Cities * Waymo’s Robot Minivans to Operate in Bay Area for First Time Since Covid-19 Outbreak

  • GlobeNewswire

    Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

    – Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China.

  • GlobeNewswire

    Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program

    LONDON, May 14, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib,.

  • Reuters

    SE Asia Stocks-Rise as China signals more policy measures to support economy

    * Thai shares rise 1.7% * Indonesia mulls reopening plans * Malaysian markets closed for holiday By Pranav A K May 11 (Reuters) - Southeast Asian stock markets rose on Monday, with Thai stocks leading the gains, as sentiment improved after China's central bank signalled more policy measures to support a coronavirus-hit economy. Shares in trade-reliant Thailand surged 1.7% as the People's Bank of China (PBOC) said on Sunday it would step up counter-cyclical adjustments to support the Chinese economy and make monetary policy more flexible to fend off financial risks. More policy support from China, Southeast Asia's region's biggest trading partner, has supercharged what would have been a positive start to Asian trading anyway, said Jeffrey Halley, a senior market analyst at OANDA.

  • GlobeNewswire

    Chi-Med to Attend Upcoming Investor Conferences

    LONDON, May 08, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will.

  • Should You Worry About Hutchison China MediTech Limited's (LON:HCM) CEO Pay?
    Simply Wall St.

    Should You Worry About Hutchison China MediTech Limited's (LON:HCM) CEO Pay?

    Christian Hogg became the CEO of Hutchison China MediTech Limited (LON:HCM) in 2006. This analysis aims first to...

  • ACCESSWIRE

    Edison Issues ADR Update on Hutchison China MediTech (HCM)

    LONDON, UK / ACCESSWIRE / April 22, 2020 / Notwithstanding the COVID-19 pandemic challenges, Hutchison China MediTech (NASDAQ:HCM) remains on track for potential approval and launches of two additional ...

  • GlobeNewswire

    Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings

    LONDON, April 22, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib.

  • The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement
    Benzinga

    The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 16.) * Abbott Laboratories (NYSE: ABT) (reacted to first-quarter results and an announcement concerning development of a third rapid COVID-19 screening test) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Chembio Diagnostics Inc (NASDAQ: CEMI) * DexCom, Inc. (NASDAQ: DXCM) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Eli Lilly And Co (NYSE: LLY) * Immunovant Inc (NASDAQ: IMVT) * Masimo Corporation (NASDAQ: MASI) * Moderna Inc (NASDAQ: MRNA) * Novavax, Inc. (NASDAQ: NVAX) (its Australian developmental partner said COVID-19 vaccine human testing will begin in the coming weeks) * OraSure Technologies, Inc. (NASDAQ: OSUR) * Pulmatrix Inc (NASDAQ: PULM) (granted Sensory Cloud license to its PUR 003 and PUR 006) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (announced FDA acceptance of BLA for REGN-EB3, a triple antibody cocktail treatment for Ebola virus infection, with Priority Review designation) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Thermogenesis Holdings Inc (NASDAQ: THMO) (announced FDA concurrence that its COVID-19 antibody blood test has been properly validated and can now be distributed)Down In The Dumps (Biotech stocks that hit 52-week lows April 16) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * Celcuity Inc (NASDAQ: CELC)Stocks In Focus Moderna Obtains $483M In BARDA Funding For COVID-19 Vaccine Research Moderna said the Biomedical Advanced Research and Development Authority, or BARDA, has committed up to $483 million in funding to accelerate the development of its mRNA vaccine against the novel coronavirus -- SARS-CoV-19. The agreement provides for BARDA releasing funds to get the candidate to the point of FDA licensing. Moderna also provided the likely timeline for the initiation of Phase 2 and 3 studies, with the midstage study to start in the second quarter and the late-stage study in fall 2020.The stock rallied 18.62% to $48.16 in Friday's premarket session. Gilead's Remdesivir Reportedly Found Effective In Phase 3 US Trials Gilead Sciences, Inc. (NASDAQ: GILD)'s remdesivir, which is being evaluated in clinical trials as a treatment option for SARS-CoV-2, was found to be effective, resulting in rapid recoveries in fever and respiratory symptoms, STAT reported, citing results from two Phase 3 clinical trials run by the University of Chicago Medicine.The institution's infectious disease specialist Kathleen Mullane, who is overseeing the studies in which 125 people were enrolled, reportedly said in a video discussion with her colleagues that most of the patients have already been discharged, with only two deaths occurring, STAT said.The stock was jumping 11.98% to $85.71 in premarket trading. Roche To Launch New Serology Test For SARS-CoV-2 Antibodies In May Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the virus."Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms," the company said in the release.The company said it aims to have the antibody test available by early May in countries accepting the CE mark and is actively working with the FDA for an emergency use authorization. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.See also: The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates Veracyte Expects Q1 Revenue Above Consensus Veracyte Inc (NASDAQ: VCYT) preannounced first-quarter results and said it expects revenue of $30.5 million to $31.5 million, up from $29.5 million in the year-ago quarter. Analysts estimate revenue of $30.35 million.The company also announced several measures to reduce costs amid the COVID-19 pandemic and withdrew its 2020 guidance.Chi-Med Neuroendocrine Tumor Drug Gets Fast Track Designations For 2 Indications HUTCHISON CHINA/S ADR (NASDAQ: HCM) said the FDA granted two Fast Track Designations for the development of surufatinib in the treatment of both advanced and progressive pancreatic neuroendocrine tumors and extra-pancreatic NETs in patients who are not candidates for surgery.Biofrontera Expects 5% Drop in Q1 Revenue Due to COVID-19 Impact Biofrontera AG (NASDAQ: BFRA) said its first-quarter revenue is likely to come in at 6.4 million euros to 6.6 million euros ($6.9 to $7.1 million), down about 5% from the year-ago period, as sales declines in U.S. more than offset growth in Europe.Offerings Pulmatrix said it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 4.79 million shares of its common stock at $1.671 per share in a registered direct offering priced at-the-market. The company also said it has agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 4.79 million shares. Gross proceeds from the offering are expected to be about $8 million.The stock was down 25.99% to $1.31 in the premarket session. Cutera, Inc. (NASDAQ: CUTR) said it has pricing an underwritten public offering of 2.385 million shares of its common stock at $10.50 per share to raise gross proceeds of $25 million. The offering is expected to close on or about April 21.The stock dipped was down 13.25% at $11.65 in the premarket session.Related Link:Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use See more from Benzinga * The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

    The FDA Fast Track Designation is one of several approaches utilized by the U.S. FDA to expedite development and review of potential medicines for serious conditions and that fulfill unmet medical needs. A potential new medicine may fill an unmet medical need by being the first therapy to address a specific serious condition, offer clinically significant advantages over available therapies, act via a different mechanism of action than available therapies, or have a benefit in patients who are unresponsive to or intolerant of available therapies.

  • Do Hedge Funds Love Hutchison China MediTech Limited (HCM)?
    Insider Monkey

    Do Hedge Funds Love Hutchison China MediTech Limited (HCM)?

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • GlobeNewswire

    Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China

    LONDON, March 31, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor.

  • CNW Group

    Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing

    Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing

  • International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020
    PR Newswire

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020

    Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 18th and 19th, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.

  • GlobeNewswire

    Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs

    Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT LONDON, March 03, 2020 -- Hutchison China MediTech Limited (“Chi-Med”).

  • GlobeNewswire

    Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions

    LONDON, Feb. 25, 2020 -- Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for.

  • Reuters

    RPT-FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials

    The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.

  • Reuters

    FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials

    The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.

  • GlobeNewswire

    Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

    LONDON, Feb. 10, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of.